GlobeNewswire Inc | Nov 9, 2020 07:30AM EST

November 09, 2020

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live webinar on Monday, November 16, 2020 at 8:00 a.m. ET highlighting its novel ImmunosynthenSTING-agonist ADC platform.

The presentation will review the therapeutic rationale for the development of STING-agonist ADCs including preclinical mechanistic data showing STING activation in both tumor cells and tumor-resident immune cells, the development and optimization of the Immunosynthen platform, and preclinical data supporting the Companys Immunosynthen ADC pipeline as well as the Investigational New Drug timeline for the Companys first development candidate.

The live webcast event can be accessed from the Investors & Media section of the Mersana website at www.mersana.com. To access the event by phone, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 3123546.

AboutMersanaTherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Mersanas second product candidate targeting NaPi2b-expressing tumors, XMT-1592, is an ADC created using Mersanas customizable and homogenous Dolasynthen platform. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-LookingStatementsThis press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as anticipates, believes, could, seeks, estimates, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Companys product candidates and new platforms will take longer and/or cost more than planned and that the identification of new product candidates will take longer than planned, as well as those listed in the Companys Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (SEC) and subsequent SEC filings. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contact:

Investor & Media ContactSarah Carmody, 617-844-8577scarmody@mersana.com